Is Amyloid Burden Measured by 18F-Flutemetamol PET Associated with Progression in Clinical Alzheimer's Disease?

被引：5

作者：

Muller, Ebba Gloersen ^{[1
,2
]}

Edwin, Trine Holt ^{[3
,4
,5
]}

Strand, Bjorn Heine ^{[4
,5
,6
]}

Stokke, Caroline ^{[1
,7
]}

Revheim, Mona Elisabeth ^{[1
,2
]}

Knapskog, Anne-Brita ^{[4
]}

机构：

[1] Oslo Univ Hosp, Dept Nucl Med, Div Radiol & Nucl Med, Oslo, Norway

[2] Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway

[3] Univ Oslo, Fac Med, Inst Hlth & Soc, Oslo, Norway

[4] Oslo Univ Hosp, Dept Geriatr Med, Oslo, Norway

[5] Vestfold Hosp Trust, Norwegian Natl Advisory Unit Ageing & Hlth, Tonsberg, Norway

[6] Norwegian Inst Publ Hlth, Dept Chron Dis & Ageing, Oslo, Norway

[7] Univ Oslo, Dept Phys, Oslo, Norway

来源：

JOURNAL OF ALZHEIMERS DISEASE | 2022年 / 85卷 / 01期

关键词：

Alzheimer's disease; amyloid-beta; clinical progression; Flutemetamol; PET-CT; trajectories; MILD COGNITIVE IMPAIRMENT; DIAGNOSTIC GUIDELINES; HYPOTHETICAL MODEL; NATIONAL INSTITUTE; DEMENTIA; RECOMMENDATIONS; WORKGROUPS; VALIDITY; DECLINE; SCALE;

D O I：

10.3233/JAD-215046

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Background: Patients with Alzheimer's disease (AD) show heterogeneity in clinical progression rate, and we have limited tools to predict prognosis. Amyloid burden from F-18-Flutemetamol positron emission tomography (PET), as measured by standardized uptake value ratios (SUVR), might provide prognostic information. Objective: We investigate whether F-18-Flutemetamol PET composite or regional SUVRs are associated with trajectories of clinical progression. Methods: This observational longitudinal study included 94 patients with clinical AD. PET images were semi-quantified with normalization to pons. Group-based trajectory modeling was applied to identify trajectory groups according to change in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) over time. Multinomial logistic regression models assessed the association of SUVRs with trajectory group membership. Results: Three trajectory groups were identified. In the regression models, neither composite nor regional SUVRs were associated with trajectory group membership. Conclusion: There were no associations between CDR progression and F-18-Flutemetamol PET-derived composite SUVRs or regional SUVRs in clinical AD.

引用

页码：197 / 205

页数：9

共 46 条

[1] Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis [J].

Ackley, Sarah F. ;

Zimmerman, Scott C. ;

Brenowitz, Willa D. ;

Tchetgen, Eric J. Tchetgen ;

Gold, Audra L. ;

Manly, Jennifer J. ;

Mayeda, Elizabeth Rose ;

Filshtein, Teresa J. ;

Power, Melinda C. ;

Elahi, Fanny M. ;

Brickman, Adam M. ;

Glymour, M. Maria .

BMJ-BRITISH MEDICAL JOURNAL, 2021, 372

[2] The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease [J].

Albert, Marilyn S. ;

DeKosky, Steven T. ;

Dickson, Dennis ;

Dubois, Bruno ;

Feldman, Howard H. ;

Fox, Nick C. ;

Gamst, Anthony ;

Holtzman, David M. ;

Jagust, William J. ;

Petersen, Ronald C. ;

Snyder, Peter J. ;

Carrillo, Maria C. ;

Thies, Bill ;

Phelps, Creighton H. .

ALZHEIMERS & DEMENTIA, 2011, 7 (03) :270-279

[3] Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison [J].

Altomare, Daniele ;

Caprioglio, Camilla ;

Assal, Frederic ;

Allali, Gilles ;

Mendes, Aline ;

Ribaldi, Federica ;

Ceyzeriat, Kelly ;

Martins, Marta ;

Tomczyk, Szymon ;

Stampacchia, Sara ;

Dodich, Alessandra ;

Boccardi, Marina ;

Chicherio, Christian ;

Frisoni, Giovanni B. ;

Garibotto, Valentina .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (07) :2200-2211

[4]

Brakhus Anne, 2011, Tidsskr Nor Laegeforen, V131, P2254, DOI 10.4045/tidsskr.11.0786

[5] Validation of an electronic image reader training programme for interpretation of [18F]flutemetamol β- amyloid PET brain images [J].

Buckley, Christopher J. ;

Sherwin, Paul F. ;

Smith, Adrian P. L. ;

Wolber, Jan ;

Weick, Sharon M. ;

Brooks, David J. .

NUCLEAR MEDICINE COMMUNICATIONS, 2017, 38 (03) :234-241

[6] Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework [J].

Chiotis, Konstantinos ;

Saint-Aubert, Laure ;

Boccardi, Marina ;

Gietl, Anton ;

Picco, Agnese ;

Varrone, Andrea ;

Garibotto, Valentina ;

Herholz, Karl ;

Nobili, Flavio ;

Nordberg, Agneta .

NEUROBIOLOGY OF AGING, 2017, 52 :214-227

[7] Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials [J].

Coley, Nicola ;

Andrieu, Sandrine ;

Jaros, Mark ;

Weiner, Michael ;

Cedarbaum, Jesse ;

Vellas, Bruno .

ALZHEIMERS & DEMENTIA, 2011, 7 (06) :602-610

[8] The FDA Approves Aducanumab for Alzheimer's Disease, Raising Important Scientific Questions [J].

de la Torre, Jack C. ;

Gonzalez-Lima, Francisco .

JOURNAL OF ALZHEIMERS DISEASE, 2021, 82 (03) :881-882

[9] Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study [J].

Dubois, Bruno ;

Epelbaum, Stephane ;

Nyasse, Francis ;

Bakardjian, Hovagim ;

Gagliardi, Geoffroy ;

Uspenskaya, Olga ;

Houot, Marion ;

Lista, Simone ;

Cacciamani, Federica ;

Potier, Marie-Claude ;

Bertrand, Anne ;

Lamari, Foudil ;

Benali, Habib ;

Mangin, Jean-Francois ;

Colliot, Olivier ;

Genthon, Remy ;

Habert, Marie-Odile ;

Hampel, Harald .

LANCET NEUROLOGY, 2018, 17 (04) :335-346

[10] A high cerebrospinal fluid soluble TREM2 level is associated with slow clinical progression of Alzheimer's disease [J].

Edwin, Trine Holt ;

Henjum, Kristi ;

Nilsson, Lars N. G. ;

Watne, Leiv Otto ;

Persson, Karin ;

Eldholm, Rannveig Sakshaug ;

Saltvedt, Ingvild ;

Halaas, Nathalie Bodd ;

Selbaek, Geir ;

Engedal, Knut ;

Strand, Bjorn Heine ;

Knapskog, Anne-Brita .

ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2020, 12 (01)

← 1 2 3 4 5 →